# Serina Therapeutics (SER) — News

SER · AMEX · Stock

Canonical page: https://www.lighthorse.io/tickers/ser/news

## Recent headlines

- [Trading halt: Aztr (AMEX) - Regulatory concern](https://www.ainvest.com/news/trading-halt-aztr-amex-regulatory-concern-2610) — AInvest Wire, Oct 13, 2026
  On October 13, 2026, trading for Aztr (AMEX) was temporarily suspended amid regulatory concerns, according to reports. While no official statement has been issued by the New York Stock Exchange, the halt has raised questions among investors about the company’s compliance status and operational…
- [Adani Green Generation capacity 20.8 GW at end-Sept, +24% y/y](https://www.ainvest.com/news/adani-green-generation-capacity-20-8-gw-sept-24-2610) — AInvest Wire, Oct 10, 2026
  Adani Green Energy Ltd (AGEL) has reported a significant increase in its renewable energy generation capacity, reaching 20.8 gigawatts (GW) as of the end of September 2026, representing a 24% year-over-year growth . This expansion underscores the company’s ongoing commitment to scaling India’s…
- [Serina Therapeutics - Expects to report topline data from the single-ascending-dose portion of the study in first half of 2027](https://www.ainvest.com/news/serina-therapeutics-expects-report-topline-data-single-ascending-dose-portion-study-2027-2609) — AInvest Wire, Sep 9, 2026
  Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company, has completed enrollment and dosing in Cohort 1 of its Phase 1b registrational study of SER-252, an investigational apomorphine therapy for advanced Parkinson’s disease. The milestone was achieved ahead of the…
- [Serina Therapeutics Inc: Reports cohort 1 observations from ser-252 registrational study in advanced Parkinson’s disease and advances to cohort 2](https://www.ainvest.com/news/serina-therapeutics-reports-cohort-1-observations-ser-252-registrational-study-advanced-parkinson-disease-advances-cohort-2-2609) — AInvest Wire, Sep 9, 2026
  Serina Therapeutics Inc. (NYSE American: SER) has completed enrollment and dosing in Cohort 1 of its Phase 1b registrational clinical trial evaluating SER-252, an investigational apomorphine therapy for advanced Parkinson’s disease. All eight patients in Cohort 1 were enrolled and dosed across…
- [Serina Therapeutics - May sell up to $25 mln of common stock to Roth principal investments - SEC filing](https://www.ainvest.com/news/serina-therapeutics-sell-25-mln-common-stock-roth-principal-investments-sec-filing-2608) — AInvest Wire, Aug 27, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).